Dr Stephens is a career research scientist with 20 years experience in molecular and cellular biology research. He has experience in academic and pre-clinical research, and a focus on translation and the commercialisation of research findings. He established and leads an independent academic research group at the Hudson Institute of Medical Research, investigating mechanisms that contribute to the formation, progression and dissemination of high grade, serous epithelial ovarian cancers. Since 2010, his research has focused on biomarker identification and development in ovarian cancer, and the development of therapeutic strategies to improve patient outcomes. He is also actively involved across the biotech sector, with appointments to the scientific advisory for Invion Ltd and AMTBio Pty Ltd.
Andrew Stephens
Chief Scientific Officer, Executive Director / Cleo Diagnostics
